Radiopharm Theranostics and FDA Agree on Design of Phase 3 RAD101 Trial for Brain Metastases
Radiopharm Theranostics secures FDA agreement on pivotal Phase 3 RAD101 trial, advancing its brain metastasis imaging agent toward clinical validation.
Radiopharm Theranostics secures FDA agreement on pivotal Phase 3 RAD101 trial, advancing its brain metastasis imaging agent toward clinical validation.